I'll research MET (MetLife) before writing the preview. Let me gather recent filings, transcripts, and news.Let me get the prior-year Q2 base for comparisons, recent news, and stock performance.Let me check for analyst consensus expectations and any very recent news.I have enough to write a well-grounded preview. Let me compile the key figures and write it.# MetLife (MET) — Q2 2026 Earnings Preview
MetLife heads into Q2 with the wind at its back: an easy year-over-year comparison, three straight quarters of above-plan variable investment income, and a stock that has quietly become one of the best performers in large-cap life insurance. The bar the market has set is meaningfully higher than the muted expectations that greeted this print a year ago.
The Q1 print set a high-water mark and framed year two of the "New Frontier" strategy: - Adjusted EPS $2.42, +23% YoY; adjusted earnings $1.59 billion, +18%. - Adjusted ROE 17.0%, at the top of the 15–17% target. - VII of $518 million pretax — the third consecutive above-expectation quarter, driven by ~2.9% private equity returns (venture/AI-skewed book returned 6.8%). - Direct expense ratio of 11.9%, already inside the 12.1% full-year 2026 target even while absorbing ~50 bps of PineBridge dilution. - Broad-based top line: adjusted PFOs ex-PRT +10%, with growth in every segment.
1. Variable investment income — the swing factor. VII is reported on a one-quarter lag and has run hot for three quarters. Management continues to guide to a "normalized" level over the full year, so a step-down toward run-rate would be expected and shouldn't rattle the thesis — but given how much of the recent EPS beat has been VII-driven, investors will scrutinize the private-equity and venture-capital marks (heavily AI-exposed) for signs of mean reversion.
2. Group Benefits underwriting normalization. Q1 was exceptional: the group life mortality ratio was 80.1%, well below the 83–88% target, aided by favorable working-age mortality and a light flu season. Management framed the mortality tailwind as potentially structural (COVID pull-forward, GLP-1 effects) but cautioned any pricing give-back would happen "in years, not quarters." Offsetting that, the non-medical health ratio ran hot (75.8% vs. 70–75% target) on seasonal dental utilization, disability severity, and new state paid-family-leave programs — management guided to moderation in the second half, so Q2 is a checkpoint on that call.
3. RIS spreads and the full-year guide. Core spread ex-VII was 95 bps in Q1 (down 4 bps sequentially) as MetLife rotated the large Q4 PRT inflows. Management guided Q2 core spread to be roughly flat to slightly higher, with a persistently flat yield curve as a headwind. Watch whether the full-year RIS adjusted-earnings guide of $1.6–$1.8 billion is reaffirmed, and the cadence of newer growth engines — U.K. funded reinsurance and retail annuity reinsurance ($2 billion of combined inflows YTD as of Q1).
4. Asia — momentum vs. tough comps, plus the Japan regulatory overhang. Asia was the standout in Q1 (+31% adjusted earnings; sales +22% cc, Japan +26%, Korea +44%). Management flagged moderating growth rates ahead on strong prior-year comps but expected momentum to persist. Separately, monitor the industry-wide Japan FSA "secondment" issue — MetLife has ended the practice and is cooperating, and says there's been no impact on sales or results, but it remains an open regulatory item.
5. MIM / PineBridge integration. First full quarter post-close delivered $47 million (+68%), but Q1 saw ~$2 billion of institutional outflows tied to platform integration and market volatility. Management said flows stabilized late in Q1 and into April, with a strong private-assets pipeline and cross-sell opportunities (~50% of PineBridge AUM is non-U.S.). Watch for stabilizing/positive net flows and the promised earnings ramp through the year.
6. Latin America and EMEA. LatAm carries a Mexico VAT tax drag (Q1 earnings +5% reported but -9% cc); watch underlying volume growth (sales +20% cc in Q1). EMEA has been on a multi-year run — management raised its quarterly run-rate framing to the middle-to-upper end of $90–$100 million.
Capital return remains a core part of the story: - ~$750 million of buybacks in Q1 plus ~$200 million in April; ~$1.1 billion remaining on authorization. Watch the Q2 repurchase pace and any refresh of the authorization. - Dividend raised 4.4% to $0.5925/quarter. - Holdco cash of $3.9 billion (top of the $3–$4 billion target); U.S. RBC of 379% vs. 360% target; Japan ESR expected mid-range (170–190%). - Management reiterates a 65–75% free cash flow ratio and a 24–26% adjusted tax rate through New Frontier.
MET has been a strong performer: shares are up roughly 20% year-to-date (from ~$80 in early January to ~$96) and about 40% off the mid-March lows near $68, outpacing peer Prudential (PRU up ~9% YTD). The rally accelerated into July, meaning expectations and valuation have re-rated — a clean, in-line quarter may not be enough; the burden of proof has shifted toward demonstrating the earnings power is repeatable rather than VII-flattered.
The direction of travel is favorable — easy comp, expense discipline running ahead of target, strong international sales, and disciplined capital return. The key judgment calls for investors will be: (1) how much of the beat is VII-driven vs. core; (2) whether Group Benefits non-medical health normalizes as promised; (3) confirmation of the RIS full-year guide and spread trajectory; and (4) MIM flow stabilization. With the stock having already run hard, quality of earnings and management's tone on the full-year outlook likely matter more than the headline number.
Sources: MetLife Q1 2026 earnings call transcript and release (May 2026); Q2 2025 earnings release (August 2025); consensus estimates and price data as of Aug 4, 2026. Figures are management-reported adjusted (non-GAAP) measures unless noted.